April 10 (Reuters) - Keros Therapeutics KROS.O said on Thursday its board had authorized a stockholder rights plan, also known as a "poison pill", in response to rapid accumulations of the company's stock by some investors.
The company also said it had launched a process to evaluate strategic alternatives, including a possible sale of the company.
(Reporting by Manas Mishra in Bengaluru; Editing by Shilpi Majumdar)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。